Press ReleasesPress ReleasesAll Press Releases March 16, 2023Press ReleaseModra Pharmaceuticals Announces U.S. Patent Issuance for ModraDoc006/rRead MoreMay 27, 2022Press ReleaseModra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual MeetingRead MoreMay 23, 2022Press ReleaseModra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate CancerRead MoreFebruary 17, 2022Press ReleaseModra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual MeetingRead MoreApril 27, 2021Press ReleaseModra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical DevelopmentRead MoreFebruary 12, 2021Press ReleaseModra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual MeetingRead MoreFebruary 11, 2021Press ReleaseModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPCRead MoreAugust 14, 2019Press ReleaseModra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer TrialRead More
March 16, 2023Press ReleaseModra Pharmaceuticals Announces U.S. Patent Issuance for ModraDoc006/rRead More
May 27, 2022Press ReleaseModra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual MeetingRead More
May 23, 2022Press ReleaseModra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate CancerRead More
February 17, 2022Press ReleaseModra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual MeetingRead More
April 27, 2021Press ReleaseModra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical DevelopmentRead More
February 12, 2021Press ReleaseModra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual MeetingRead More
February 11, 2021Press ReleaseModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPCRead More
August 14, 2019Press ReleaseModra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer TrialRead More
